Duchenne muscular dystrophy (DMD) is a X-linked recessive disorder due to a mutation of the dystrophin gene (Xp21). Dystrophin is a sarcolemmal protein of skeletal and cardiac muscle, and its absence causes progressive muscle degeneration and substitution with fat and connective tissue. The progressive muscle degeneration leads to loss of autonomous walking before the age of 15 years and death for cardiac and/or respiratory failure. There are no specific treatment for DMD, and the standard of care is now based on long-term corticosteroid (CS) use. The studies on bone mass in DMD are very few, but they agree in reporting the presence of a reduced bone mass and an increased rate of fractures probably due to long-term steroid therapy and disuse-osteopenia. The aim of this study, involving 20 ambulant DMD boys (age 7-10 years) has been the evaluation of the effects of low-level mechanical vibrations on bone in a group of ambulant DMD children for 1 year, with RDA-adjusted dietary calcium intake and 25OH vitamin D supplementation.
All children were instructed to have a daily intake of calcium equal to the 100% of the RDA and were supplemented with calcifediol (0.7 mcg/kg/die). The 20 boys were randomly assigned to two groups: group 1 (mechanical intervention group) = a mechanical device (a small platform designed to induce vertical, sinusoidal acceleration) was installed in the home of each boy of group 1. group 2 (placebo control group) = a placebo device was installed in the home of each boy of group 2 All boys were instructed to stand on the platform for 10 minutes each day for 12 months. Compliance was followed and stimulated through weekly telephone contacts with parents and children.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
20
Small platform designed to induce vertical, sinusoidal acceleration.
Small platform designed to NOT induce vertical, sinusoidal acceleration
Change in bone mineral density at lumbar spine.
Bone mineral density evaluated by DXA. Bone mineral apparent density calculated to correct for bone size (growing subjects). Z-score calculated. Measurements: baseline and 12 months.
Time frame: baseline and 12th month
Calcium
changes in serum calcium (mg/dL)
Time frame: baseline and 12th month
Phosphate
changes in serum phosphate (mg/dL)
Time frame: baseline and 12th month
Magnesium
changes in serum magnesium (mg/dL)
Time frame: baseline and 12th month
Creatinine
changes in serum creatinine (mg/dL)
Time frame: baseline and 12th month
Bone Alkaline Phosphatase
changes in serum bone alkaline phosphatase (µg/L)
Time frame: baseline and 12th month
Osteocalcin
changes in serum osteocalcin (µg/L)
Time frame: baseline and 12th month
Parathyroid Hormone
changes in serum parathyroid hormone (ng/L)
Time frame: baseline and 12th month
25-OH vitamin D
changes in serum 25-OH vitamin D (µg/L)
Time frame: baseline and 12th month
1,25(OH)2 vitamin D
changes in serum 1,25(OH)2 vitamin D (ng/L)
Time frame: baseline and 12th month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.